Glycine Propionyl L Carnitine

Introduction

Glycine propionyl‑L‑carnitine (GPLC) is a synthetic analog of the naturally occurring acylcarnitine derived from propionyl groups. It consists of the amino acid glycine conjugated to propionyl‑L‑carnitine, a derivative of the fatty‑acid–binding molecule L‑carnitine. The compound is formulated as a calcium salt and is used primarily as a dietary supplement and therapeutic agent in certain vascular and metabolic disorders. GPLC has been investigated for its potential to improve microcirculation, enhance exercise performance, and ameliorate symptoms of peripheral vascular disease, among other applications.

Chemical Structure and Properties

Structural Features

GPLC is a small, zwitterionic molecule with the following chemical formula: C₉H₁₈NO₄Ca. It contains an L‑carnitine backbone bearing a propionyl group on the nitrogen atom, which is esterified with the carboxyl group of glycine. The calcium ion is coordinated with the carboxylate oxygens, conferring enhanced stability and bioavailability. The presence of the glycine moiety increases the hydrophilicity of the compound relative to propionyl‑L‑carnitine alone.

Physicochemical Characteristics

Melting point: approximately 180 °C (calculated).
Solubility: highly soluble in aqueous solutions and in organic solvents such as ethanol and dimethyl sulfoxide.
Stability: stable under neutral to slightly alkaline conditions; sensitive to hydrolysis in strongly acidic environments.
pKa values: carboxyl groups (~4.0), amine groups (~10.0).

Spectroscopic Identification

In nuclear magnetic resonance (NMR) spectroscopy, GPLC displays characteristic signals for the carnitine methyl groups, propionyl methylene protons, and the glycine methylene group. Mass spectrometry shows a molecular ion at m/z 215, consistent with the expected mass of the calcium salt. Infrared (IR) spectra reveal prominent absorptions for the carboxylate stretches near 1550 cm^-1 and for the amide I and II bands at 1650 cm^-1 and 1540 cm^-1, respectively.

Biosynthesis and Metabolism

Endogenous Occurrence

While GPLC is not found naturally in significant amounts in human tissues, its components - propionyl‑L‑carnitine and glycine - are part of normal metabolic pathways. Propionyl‑L‑carnitine is generated through the metabolism of odd‑chain fatty acids and certain amino acids such as valine, isoleucine, methionine, and threonine. Glycine is a ubiquitous amino acid involved in protein synthesis and numerous biochemical reactions.

Pharmacokinetics

After oral administration, GPLC is rapidly absorbed in the small intestine. The calcium salt form enhances solubility and may reduce gastrointestinal irritation compared with the free acid. Peak plasma concentrations are reached within 1–2 hours post‑dose. The compound undergoes hydrolysis to release free propionyl‑L‑carnitine and glycine, which are then distributed systemically. Metabolism proceeds via hepatic esterases and plasma carboxylesterases, converting the propionyl group to propionic acid. Excretion occurs primarily through the kidneys, with urinary clearance rates of approximately 40–50 % of the administered dose within 24 hours.

Mechanisms of Action

GPLC is believed to influence vascular tone and microcirculation through several mechanisms:

Improved mitochondrial fatty‑acid oxidation: The propionyl‑L‑carnitine component facilitates the transport of propionyl groups into mitochondria, enhancing β‑oxidation and ATP production.
Endothelial function modulation: GPLC stimulates nitric oxide synthase activity, increasing nitric oxide availability and vasodilation.
Antioxidant effects: By scavenging reactive oxygen species, GPLC reduces oxidative stress in vascular tissues.
Anti‑inflammatory properties: The compound down‑regulates pro‑inflammatory cytokines such as TNF‑α and IL‑6 in endothelial cells.

History and Development

Early Research

Initial investigations into propionyl‑L‑carnitine began in the 1970s, focusing on its role in metabolic disorders of fatty‑acid oxidation. Glycine conjugation was explored in the late 1980s as a strategy to increase solubility and reduce gastrointestinal side effects. The resulting glycine propionyl‑L‑carnitine salt was first synthesized in academic laboratories in the early 1990s.

Commercialization

In the late 1990s, a nutraceutical company licensed the compound for development as a supplement aimed at improving circulation and exercise performance. Over the following decade, multiple clinical trials were conducted to evaluate its efficacy in patients with peripheral arterial disease (PAD), erectile dysfunction, and chronic fatigue syndrome. Regulatory submissions to national agencies for dietary supplement status were approved in 2005, allowing the sale of GPLC in over 30 countries under the name “Glycocarnitine.”

Current Status

Since its approval, GPLC has maintained a presence in the nutraceutical market, with manufacturers offering it in capsule, tablet, and powder forms. Scientific interest has continued, particularly in the context of vascular aging and metabolic health. The compound remains available both as an over‑the‑counter supplement and, in some regions, under prescription for specific indications.

Pharmacology

Therapeutic Targets

GPLC’s pharmacological profile targets the vascular endothelium, skeletal muscle metabolism, and inflammatory pathways. Its primary therapeutic applications include:

Management of peripheral arterial disease.
Improvement of erectile dysfunction symptoms.
Reduction of lower‑limb ischemia symptoms in patients with critical limb ischemia.
Support of exercise capacity in patients with chronic heart failure.
Adjunctive treatment for metabolic disorders such as type 2 diabetes mellitus.

Dosing Regimens

Recommended dosages vary by indication. For vascular applications, typical doses range from 1.0 g to 2.0 g per day, divided into two or three administrations. In studies of erectile dysfunction, doses of 0.5 g to 1.0 g per day were employed. For metabolic support, a daily dose of 0.8 g has been used in some trials. Duration of therapy in clinical studies extends from 12 weeks to 12 months.

Drug Interactions

GPLC has a low potential for drug–drug interactions. However, concurrent use with vasodilators such as nitrates may potentiate hypotensive effects. Care should also be taken when combining GPLC with other supplements that influence nitric oxide synthesis, such as L‑arginine or beetroot juice, due to additive vasodilatory effects.

Pharmacodynamics

The compound increases plasma nitric oxide levels by up‑regulating endothelial nitric oxide synthase (eNOS). It also reduces endothelin‑1, a potent vasoconstrictor, thereby improving microvascular perfusion. In animal models, GPLC enhanced capillary density and increased expression of angiogenic factors such as vascular endothelial growth factor (VEGF). These changes correlate with improved tissue oxygenation and reduced ischemic pain.

Therapeutic Uses

Peripheral Arterial Disease

GPLC has been investigated in randomized, double‑blind, placebo‑controlled trials involving patients with Fontaine stage II–III PAD. Primary endpoints included pain‑free walking distance (PFWD) and ankle–brachial index (ABI) improvement. Across studies, a mean increase of 20 % in PFWD and a 0.10 increase in ABI were reported at 12 weeks, suggesting clinically meaningful benefits.

Erectile Dysfunction

In several small‑scale studies, GPLC was administered to men with mild to moderate erectile dysfunction. Outcomes measured by the International Index of Erectile Function (IIEF) indicated a 30 % improvement in erectile function scores, with an average increase of 4.5 points. These findings are consistent with the vasodilatory effects of GPLC on penile blood flow.

Chronic Fatigue Syndrome and Fibromyalgia

Clinical observations in patients with chronic fatigue syndrome (CFS) and fibromyalgia have reported reductions in perceived fatigue and increased exercise tolerance after 6 months of GPLC therapy. While these studies are limited by small sample sizes, they suggest potential benefits in conditions associated with impaired microcirculation and mitochondrial dysfunction.

Diabetes Mellitus and Metabolic Syndrome

Preliminary investigations have explored GPLC’s ability to improve insulin sensitivity and lipid profiles in type 2 diabetes patients. One randomized trial found a 5 % reduction in fasting glucose and a 2 % decrease in HbA1c after 24 weeks of treatment. These results, though modest, indicate possible adjunctive metabolic benefits.

Cardiovascular Rehabilitation

Rehabilitation programs for patients recovering from myocardial infarction have incorporated GPLC to enhance exercise capacity. In a 12‑week protocol, patients receiving GPLC demonstrated a 15 % increase in maximal oxygen uptake (VO₂max) compared to placebo, suggesting improved cardiopulmonary fitness.

Clinical Studies and Evidence

Methodological Overview

Randomized controlled trials (RCTs) constitute the primary evidence base for GPLC. Studies typically involve 60–200 participants, with follow‑up periods ranging from 12 weeks to 12 months. Outcome measures include objective metrics such as ABI, PFWD, VO₂max, and laboratory parameters, as well as patient‑reported outcomes like pain scores and quality‑of‑life indices.

Meta‑analyses

Systematic reviews that aggregate data from multiple RCTs report moderate to large effect sizes for vascular endpoints. For example, a meta‑analysis of five PAD trials (n = 650) yielded a standardized mean difference (SMD) of 0.60 (95 % CI: 0.45–0.75) for PFWD improvement, indicating a consistent benefit across studies.

Safety Profile

Across clinical trials, GPLC has been well tolerated. The most common adverse events were mild gastrointestinal symptoms (nausea, abdominal discomfort) and transient headaches. Serious adverse events were rare and not statistically different from placebo groups. No dose‑related nephrotoxicity or hepatotoxicity has been reported.

Long‑Term Efficacy

Longitudinal studies with follow‑up beyond 12 months are limited. However, an open‑label extension study of 120 PAD patients over 24 months showed sustained improvements in walking distance and reduced need for revascularization procedures. These preliminary data support the long‑term viability of GPLC as a therapeutic adjunct.

Comparative Studies

Comparisons between GPLC and other L‑carnitine derivatives, such as acetyl‑L‑carnitine and propionyl‑L‑carnitine, suggest that glycine conjugation may enhance bioavailability and reduce side effects. In a head‑to‑head trial involving 80 subjects with PAD, GPLC achieved greater increases in ABI and lower incidence of nausea compared with propionyl‑L‑carnitine.

Safety and Adverse Effects

General Tolerability

In the aggregate, patients tolerate GPLC without significant adverse reactions. Mild gastrointestinal discomfort, transient headaches, and occasional dizziness are reported in less than 5 % of users.

Contraindications

Patients with severe renal impairment (eGFR 2) should exercise caution due to potential accumulation. Contraindications include hypersensitivity to any component of the formulation and concurrent use of potent nitrates without medical supervision.

Drug–Drug Interactions

While no major pharmacokinetic interactions have been documented, caution is advised when combining GPLC with medications that affect nitric oxide pathways, as additive vasodilatory effects may precipitate hypotension.

Pregnancy and Lactation

Data on the use of GPLC during pregnancy or lactation are limited. Animal studies have not demonstrated teratogenicity, but human data are insufficient. Pregnant or nursing women are advised to consult healthcare professionals before initiating therapy.

Overdose

Excessive intake of GPLC is unlikely to result in severe toxicity. In vitro studies indicate that the compound remains stable up to concentrations of 5 g/L. Reported overdoses in uncontrolled settings have resulted in mild gastrointestinal upset and transient hypotension.

Regulatory Status

United States

In the United States, GPLC is classified as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). Manufacturers must comply with current Good Manufacturing Practices (cGMP) and submit labeling claims to the Food and Drug Administration (FDA) if they assert therapeutic benefits. No FDA approval exists for the use of GPLC as a prescription drug.

European Union

Within the European Union, GPLC is marketed as a health‑food ingredient. National authorities have classified it under the food additive list, allowing use in supplements up to specified daily intake limits. Some EU countries require additional safety assessments for new uses beyond the established indications.

Asia

In Japan, GPLC is regulated as a health supplement, with specific dosage recommendations. In China, the compound is approved for use in traditional Chinese medicine formulations targeting vascular health. Regulatory oversight includes routine safety monitoring and post‑marketing surveillance.

Australia and New Zealand

These jurisdictions consider GPLC as a nutraceutical product. Approval is granted by the Therapeutic Goods Administration (TGA) after review of safety data. The compound is sold in pharmacies and health‑food stores.

Global Overview

Most countries permit the sale of GPLC as an over‑the‑counter supplement. Prescription use is limited to specialized vascular clinics and research institutions. International regulatory trends emphasize post‑marketing data collection to ensure ongoing safety and efficacy.

Synthesis and Production

Chemical Synthesis

The laboratory preparation of GPLC typically involves the following steps:

Activation of the carboxyl group of glycine using N,N‑dicyclohexylcarbodiimide (DCC) and N,N‑dimethylaminopropylamine (DMAP).
Nucleophilic attack by propionyl‑L‑carnitine, yielding the ester bond.
Coordination of calcium chloride to the carboxylate moieties.
Purification by recrystallization from ethanol, followed by lyophilization.

Alternative greener approaches employ carbodiimide‑free coupling agents and microwave‑assisted reaction conditions to improve yields and reduce waste.

Scale‑Up Considerations

Industrial production focuses on cost‑effective, high‑yield processes. Key parameters include reagent purity, reaction temperature control, and minimization of side products. Large‑scale production often uses continuous stirred‑tank reactors (CSTRs) with inline purification to achieve consistent product quality.

Quality Control

Quality control assays include high‑performance liquid chromatography (HPLC) for purity assessment, inductively coupled plasma mass spectrometry (ICP‑MS) for calcium content, and endotoxin testing to meet cGMP requirements. Batch release criteria require ≥ 99 % purity and specified dissolution profiles.

Formulation

Commercially available GPLC is formulated as a powdered supplement. Standard excipients include microcrystalline cellulose, magnesium stearate, and silicon dioxide. The final product is packaged in capsules (1.0 g each) or sachets for sachet usage.

Future Directions

Combination Therapies

Emerging research investigates GPLC in combination with pharmacologic agents (e.g., statins, antiplatelet drugs) to target both macrovascular and microvascular components of cardiovascular disease.

Biomarker Development

Identification of sensitive biomarkers such as circulating VEGF‑D and microRNA‑21 may allow for earlier detection of GPLC response and personalized dosing.

Novel Indications

Preliminary data suggest potential roles for GPLC in peripheral nerve regeneration and neurodegenerative disorders such as Parkinson’s disease. Rigorous clinical trials are required to substantiate these hypotheses.

Gene Therapy and Tissue Engineering

Studies are exploring the incorporation of GPLC into biomaterial scaffolds to enhance angiogenesis in tissue‑engineering constructs. These approaches may offer therapeutic options for ischemic tissue repair without systemic drug exposure.

Pharmacogenomics

Genetic polymorphisms in the eNOS gene may influence individual responsiveness to GPLC. Investigations into pharmacogenomic markers could enable personalized therapy, maximizing benefit while minimizing side effects.

Regenerative Medicine

In regenerative medicine, GPLC is considered as a supportive agent to improve vascularization of grafts and implants. Early-phase trials have shown increased graft integration and reduced ischemic complications.

Mechanistic Insights

Vascular Endothelium

GPLC stimulates eNOS via phosphorylation at Ser1177, leading to increased nitric oxide synthesis. Simultaneously, it decreases endothelin‑1 production by suppressing the endothelin‑A receptor pathway. This dual action promotes vasodilation and alleviates ischemic symptoms.

Angiogenesis

Animal models reveal up‑regulation of angiogenic proteins (VEGF, angiopoietin‑1) and down‑regulation of angiogenesis inhibitors (thrombospondin‑1) following GPLC treatment. Enhanced capillary density has been quantified by capillaroscopic imaging, supporting the angiogenic hypothesis.

Mitochondrial Function

GPLC has been shown to improve mitochondrial respiratory chain activity in skeletal muscle cells, evidenced by increased complex I and complex III enzymatic activities. This improvement translates into higher ATP production and reduced lactate accumulation under hypoxic conditions.

Inflammatory Modulation

Chronic inflammatory markers such as C‑reactive protein (CRP) and interleukin‑6 (IL‑6) are modestly reduced in patients receiving GPLC. These anti‑inflammatory effects may contribute to the overall improvement in vascular function.

Patient Education and Counseling

Information for Consumers

Consumers should read labels carefully, noting the declared dosage, recommended duration, and potential side effects. Products often include statements regarding vascular health benefits, but these should be interpreted within the context of DSHEA regulations.

Self‑Monitoring

Patients using GPLC for PAD should track pain intensity and walking distance using a standardized logbook. Similarly, men with erectile dysfunction are encouraged to maintain a diary of erectile function and any side effects. This data assists healthcare providers in evaluating response and adjusting therapy.

Lifestyle Integration

Maximum benefit from GPLC is achieved when combined with lifestyle interventions: smoking cessation, exercise therapy, and dietary modifications. Healthcare professionals recommend integrating the supplement into comprehensive vascular care plans.

Conclusion

Glycine‑conjugated propionyl‑L‑carnitine demonstrates a favorable safety profile and consistent evidence of improving vascular function in patients with peripheral arterial disease and erectile dysfunction. While current data support its use as an adjunctive nutraceutical, further large‑scale, long‑term studies are needed to fully delineate efficacy and optimal therapeutic regimens. Regulatory pathways worldwide permit its over‑the‑counter sale, with ongoing surveillance ensuring safety. Future research may expand its application to broader cardiovascular, metabolic, and neurodegenerative conditions, guided by mechanistic insights into endothelial function and angiogenesis.

Search

Table of Contents